anti-BCL2-Like 2 (BCL2L2) Antibodies

Human BCL2-Like 2 (BCL2L2) interaction partners

1. BCL-W contributes to the threshold of anti-apoptotic activity during mitosis

2. we demonstrated that miR (show MLXIP Antibodies)-126-5p plays an inhibitory role in human cervical cancer progression, regulating the apoptosis of cancer cells via directly targeting Bcl2l2.

3. High expression of Bcl-w was associated with mesenchymal changes and invading populations in the glioblastoma multiforme; Bcl-w functions as a positive regulator of invasion by enhancing mesenchymal traits of glioblastoma multiforme, consequently contributing to malignancy.

4. BCL2L2 was the virtual target of miR (show MLXIP Antibodies)-133b, and we found a negative regulatory relationship between miR (show MLXIP Antibodies)-133b and BCL2L2. MiR (show MLXIP Antibodies)-133b and BCL2L2 interfered with the viability and apoptosis of cells.

5. overexpression of miR (show MLXIP Antibodies)-15a in the FaDu cells was associated with significantly decreased BCL2L2 and BCL2 (show BCL2 Antibodies) expression and a significant increase in the apoptosis rate. The opposite results were observed in HPV-positive HSCC, where downregulation of miR (show MLXIP Antibodies)-15a suppressed apoptosis

6. we conclude that BER treatment reduces cisplatin resistance of gastric cancer cells by modulating the miR (show MLXIP Antibodies)-203/Bcl-w apoptotic axis. BER may be a novel agent to enhance chemotherapeutic responses in cisplatin-resistant gastric cancer patients

7. Genetic and pharmacological inhibition of BCL-W and BCL-XL (show BCL2L1 Antibodies) causes directed elimination of senescent cells.

8. Data show that BCL2-like 2 protein (BCL2L2) is a direct target of micrRNA miR (show MLXIP Antibodies)-29b.

9. these results indicate that miR (show MLXIP Antibodies)-335 acts as a novel tumor suppressor to regulate ccRCC cell proliferation and invasion through downregulation of BCL-W expression.

10. miR (show MLXIP Antibodies)-15a acts as a tumor suppressor in NSCLC by directly targeting BCL2L2 and may serve as a potential diagnostic biomarker and therapeutic target for NSCLC.

Mouse (Murine) BCL2-Like 2 (BCL2L2) interaction partners

1. MYC (show MYC Antibodies) regulates BCL-W expression through its transcriptional regulation of specific miR (show MLXIP Antibodies).

2. Genetic and pharmacological inhibition of BCL-W and BCL-XL (show BCL2L1 Antibodies) causes directed elimination of senescent cells.

3. NF-kappaB (show NFKB1 Antibodies) p65 (show NFkBP65 Antibodies)/p52 (show GTF2H4 Antibodies) signaling mediated the effects of GDNF on Bcl-2 (show BCL2 Antibodies) and Bcl-w expressions

4. Target-derived neurotrophins coordinate transcription of the antiapoptotic gene bclw with transport of bclw mRNA to the axon, and thereby prevent axonal degeneration in rat and mouse sensory neurons.

5. By using human cancer cells and mouse embryonic fibroblasts, the study shows that Bcl-w functions in the mitochondria to increase the levels of reactive oxygen species (ROS (show ROS1 Antibodies)), which subsequently stimulates the invasion-promoting signaling pathway.

6. Bcl-2 (show BCL2 Antibodies), Bcl-x(L (show BCL2L1 Antibodies)) and Bcl-w have only minor roles in thymic lymphoma development elicited by defects in p53 (show TP53 Antibodies), and this may indicate that Mcl-1 (show MCL1 Antibodies) and/or A1 may feature more prominently in this process.

7. Induction of autocrine Bcl-w signaling through pericytes promoting endothelial cell survival is associated with melanoma development.

8. Bcl-w(-/-) sensory neurons exhibit mitochondrial abnormalities, including alterations in axonal mitochondrial size, axonal mitochondrial membrane potential, and cellular ATP levels.

9. Bcl-x(L) and Bcl-w target protein phosphatase 1alpha to Bad

10. Bcl-2 (show BCL2 Antibodies), Bcl-w, and Bax (show BAX Antibodies) act in a redundant manner in regulating granulocyte survival and death

Cow (Bovine) BCL2-Like 2 (BCL2L2) interaction partners

1. Chromosome mapping of BCL2L2 gene in cows.